Pembrolizumab: all 1,753 studies that test it

Page 5 of 18. Open to participants first (418), then studies with results posted, then the rest; newest registration first within each.

• Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)RecruitingNCT03760575Phase 1
• Pembrolizumab in Treating Participants With LeukoplakiaRecruitingNCT03603223Phase 2
• Melanoma Metastasized to the Brain and SteroidsRecruitingNCT03563729Phase 2
• VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or LymphomaRecruitingNCT03556228Phase 1/2
• Concomitant Immune Check Point Inhibitor With Radiochemotherapy in Head And Neck CancerRecruitingNCT03532737Phase 2
• A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid TumorsRecruitingNCT03526835Phase 1/2
• Trial of Pembrolizumab in Metastatic Castration Resistant Prostate CancerRecruitingNCT03506997Phase 2
• Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)RecruitingNCT03486873Phase 3
• Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer PatientsRecruitingNCT03449238Phase 1/2
• Pembrolizumab in Combination With BCG After Ablation in Patients With UUTTCC Without NephroureterectomyNot yet recruitingNCT03345134Phase 2
• Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic CancerRecruitingNCT03295227Phase 1
• A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.RecruitingNCT03219450Phase 1
• The Drug Rediscovery Protocol (DRUP Trial)RecruitingNCT02925234Phase 2
• Palbociclib and Pembrolizumab In Central Nervous System MetastasesRecruitingNCT02896335Phase 2
• A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of PembrolizumabRecruitingNCT02621021Phase 2
• A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)RecruitingNCT02332668Phase 1/2
• Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic CancerRecruitingNCT01174121Phase 2
• I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingNCT01042379Phase 2
• Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)TerminatedNCT06984328Phase 2Results posted
• A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan ExtensionActive, not recruitingNCT06212752Phase 3Results posted
• A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)Active, not recruitingNCT06099782Phase 2Results posted
• Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell CarcinomaTerminatedNCT06046482Phase 2Results posted
• Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal CancerActive, not recruitingNCT05996523Phase 2Results posted
• Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 InhibitorsTerminatedNCT05764395Phase 2Results posted
• A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)Active, not recruitingNCT05722015Phase 3Results posted
• Immunotherapy With Non-Ablative Radiation in Previously Untreated Patients With Stage IV NSCLCTerminatedNCT05691829Phase 2Results posted
• A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)TerminatedNCT05665595Phase 3Results posted
• A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical CarcinomaTerminatedNCT05634577Phase 2Results posted
• Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung CancerTerminatedNCT05617313Phase 2Results posted
• A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension StudyCompletedNCT05600309Phase 3Results posted
• A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-6598-001)CompletedNCT05594043Phase 1Results posted
• A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid TumorsTerminatedNCT05572684Phase 1/2Results posted
• A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)CompletedNCT05508867Phase 2Results posted
• A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid TumorsTerminatedNCT05491317Phase 1/2Results posted
• A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 GeneTerminatedNCT05469178Phase 1/2Results posted
• A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in Combination With BI 765063 Lead to Side Effects or Delays in SurgeryTerminatedNCT05446129Phase 1Results posted
• A Study of MK-1088 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-1088-002)TerminatedNCT05394350Phase 1/2Results posted
• A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic CancersCompletedNCT05383170Phase 1/2Results posted
• Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric CancersCompletedNCT05379972Phase 2Results posted
• A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON)TerminatedNCT05311176Phase 2Results posted
• Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal MelanomaTerminatedNCT05308901Phase 2Results posted
• Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial CancerTerminatedNCT05263492Phase 2Results posted
• A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid TumorsTerminatedNCT05256381Phase 2Results posted
• A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx CancerActive, not recruitingNCT05232851Phase 1/2Results posted
• Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)TerminatedNCT05226598Phase 3Results posted
• Study of Combined Decompressive Spine Radiosurgery and PembrolizumabTerminatedNCT05204290Early Phase 1Results posted
• A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast CancerActive, not recruitingNCT05203445Phase 2Results posted
• Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T TherapiesTerminatedNCT05191472Phase 2Results posted
• Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal CancerTerminatedNCT05167409Phase 2Results posted
• Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPCTerminatedNCT05166577Phase 1Results posted
• Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid CancerActive, not recruitingNCT05119296Phase 2Results posted
• Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).Active, not recruitingNCT05116189Phase 3Results posted
• Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)TerminatedNCT05092360Phase 3Results posted
• A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid TumorsTerminatedNCT05070247Phase 1/2Results posted
• A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)CompletedNCT05064059Phase 3Results posted
• IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATCTerminatedNCT05059470Phase 2Results posted
• Cabozantinib and Pembrolizumab in Metastatic PancreasCompletedNCT05052723Phase 2Results posted
• A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial CarcinomaTerminatedNCT05036681Phase 2Results posted
• Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic CancerCompletedNCT05014776Phase 2Results posted
• Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)CompletedNCT05008224Phase 2Results posted
• Pembrolizumab With Standard Cytotoxic Chemotherapy in Treatment Naive NSCLC Patients With Asymptomatic Brain MetastasesCompletedNCT04967417Phase 2Results posted
• Pembro+Chemo in Brain MetsTerminatedNCT04964960Phase 2Results posted
• Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)CompletedNCT04956692Phase 3Results posted
• Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell CarcinomaTerminatedNCT04955743Phase 2Results posted
• Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell CarcinomaTerminatedNCT04936841Phase 2Results posted
• Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China ExtensionCompletedNCT04934722Phase 3Results posted
• Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction CancerActive, not recruitingNCT04929392Phase 2Results posted
• Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLCTerminatedNCT04925986Phase 2Results posted
• Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension StudyCompletedNCT04924062Phase 3Results posted
• Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China ExtensionTerminatedNCT04907227Phase 3Results posted
• MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland CancerActive, not recruitingNCT04895735Phase 2Results posted
• Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).Active, not recruitingNCT04895722Phase 2Results posted
• Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China ExtensionCompletedNCT04882241Phase 3Results posted
• A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of CancersCompletedNCT04879849Phase 1Results posted
• A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)CompletedNCT04875195Phase 2Results posted
• Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell CarcinomaActive, not recruitingNCT04869137Phase 2Results posted
• Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension StudyCompletedNCT04865289Phase 3Results posted
• Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial CarcinomaTerminatedNCT04856189Phase 1/2Results posted
• A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS MutationsTerminatedNCT04854434Phase 2Results posted
• Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate CancerActive, not recruitingNCT04848337Phase 2Results posted
• Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 AntigenCompletedNCT04837196Phase 1/2Results posted
• Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver CancerCompletedNCT04828486Phase 2Results posted
• Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.TerminatedNCT04812535Phase 2Results posted
• Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC)Active, not recruitingNCT04808999Phase 2Results posted
• Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid TumorTerminatedNCT04800627Phase 1/2Results posted
• Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular CarcinomaCompletedNCT04798781Phase 2Results posted
• Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin LymphomaTerminatedNCT04788043Phase 2Results posted
• Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerActive, not recruitingNCT04781088Phase 2Results posted
• Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)CompletedNCT04776148Phase 3Results posted
• Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced MelanomaTerminatedNCT04768881Phase 2Results posted
• FLX475 Combined With Pembrolizumab in Patients With Advanced or Metastatic Gastric CancerCompletedNCT04768686Phase 2Results posted
• Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)CompletedNCT04740307Phase 2Results posted
• Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)TerminatedNCT04738487Phase 3Results posted
• TAC T-cells for the Treatment of HER2-positive Solid TumorsTerminatedNCT04727151Phase 1/2Results posted
• Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid TumorsTerminatedNCT04717375Phase 1/2Results posted
• Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)CompletedNCT04704219Phase 2Results posted
• Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint InhibitorsCompletedNCT04696055Phase 2Results posted
• Phase 2 Study of OBP-301 (Telomelysin™) in Combination With Pembrolizumab and SBRT in Patients With HNSCC With Inoperable, Recurrent or Progressive DiseaseTerminatedNCT04685499Phase 2Results posted
• Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)CompletedNCT04662710Phase 3Results posted
• Trying to Find the Correct Length of Treatment With Immune Checkpoint TherapyActive, not recruitingNCT04637594Phase 3Results posted

← Pembrolizumab overview